美药厂Novavax疫苗英国临床保护率达89.3% 惟南非测试仅49.4%
美国药厂Novavax(NVAX.US)公布其研发的新型冠状病毒疫苗最新临床试验结果,在出现变种病毒的英国3期临床试验保护率达89.3%,但在另一出现变种病毒的南非2b期临床试验保护率仅49.4%。
Novavax数据又发现,南非三份一接受疫苗测试人士有血液已有抗体,显示曾感染过旧病毒株,当中有部分测试者出现再次感染,可见患者痊癒後体内抗体或无法对付变种病毒。
《法新社》报道,Novavax指已着手制作能应对本月初才陆续出现的新病毒株的新款疫苗,预计数日後能选出理想的候选者,并於第二季着手进行可对付变种病毒的疫苗临床试验。
Novavax疫苗於英国的临床试验有1.5万名18岁至84岁的受试者,其中27%参与试验者年龄超过65岁。研究显示,Novavax疫苗对於原始新冠病毒的防护力高达95.6%,对英国变种病毒为85.6%,疫苗在英国试验的整体保护力为89.3%。但在规模较小、仅4,400多人受试的南非试验里,对南非变种病毒的防护力降到49.4%。
据悉,Novavax疫苗是较为传统的重组蛋白疫苗,疫苗含新型冠状病毒的蛋白以诱发免疫反应,优点是不含病毒遗传物质,安全性比用完整病毒制作的灭活疫苗,以及技术较新、使用病毒遗传物质的传讯核糖核酸(mRNA)疫苗都高。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.